Expertise in
13
conditions

Dr. Anirudha Dasgupta

Hematology Oncology | Oncology | Hematology
Texas Oncology PA
7848 Gateway Blvd E, 
El Paso, TX 
Accepting New Patients
Expertise in
13
conditions
Texas Oncology PA
7848 Gateway Blvd E, 
El Paso, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anirudha Dasgupta is a Hematologist Oncology specialist and an Oncologist in El Paso, Texas. Dr. Dasgupta is highly rated in 13 conditions, according to our data. His top areas of expertise are Cryoglobulinemia, Familial Mixed Cryoglobulinemia, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Dasgupta is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
Memorial Hermann Hospital System
Huntsville Memorial Hospital
Hca Houston Healthcare Conroe
Hca Houston Healthcare Kingwood
Memorial Hermann Northeast Hospital
Languages Spoken
English
Bengali
Hindi
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
7848 Gateway Blvd E, El Paso, TX 79915

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 27, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials
Similar Doctors
Expertise in
41
conditions
Dr. Pierre N. Khoury
Hematology Oncology | Oncology | Hematology
Expertise in
41
conditions
Dr. Pierre N. Khoury
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

7848 Gateway Blvd E, 
El Paso, TX 
 (0.1 miles away)
915-599-1313
Languages Spoken:
English, Arabic, Bahasa, Farsi, French, Hindi, North American Indian, Spanish
See accepted insurances
Accepting New Patients

Pierre Khoury is a Hematologist Oncology specialist and an Oncologist in El Paso, Texas. Dr. Khoury is highly rated in 41 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Khoury is currently accepting new patients.

Expertise in
17
conditions
Dr. Srini B. Reddy
Hematology Oncology | Oncology | Hematology
Expertise in
17
conditions
Dr. Srini B. Reddy
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

7848 Gateway Blvd E, 
El Paso, TX 
 (0.1 miles away)
915-599-1313
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Srini Reddy is a Hematologist Oncology specialist and an Oncologist in El Paso, Texas. Dr. Reddy is highly rated in 17 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, and Intraductal Papilloma. Dr. Reddy is currently accepting new patients.

Expertise in
18
conditions
Dr. Jingdong Su
Hematology Oncology | Hematology | Oncology
Expertise in
18
conditions
Dr. Jingdong Su
Hematology Oncology | Hematology | Oncology

Texas Oncology PA

7848 Gateway Blvd E, 
El Paso, TX 
 (0.1 miles away)
915-599-1313
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jingdong Su is a Hematologist Oncology specialist and a Hematologist in El Paso, Texas. Dr. Su is highly rated in 18 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, and Thrombocytopenia. Dr. Su is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dasgupta's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 95 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile